Evidence map›Paper›PMID 32323126›Full record

ArticleJournal of molecular neuroscience : MN2021

Stability Test of PACAP in Eye Drops.

Anita K Kovacs, Tamas Atlasz, Dora Werling, Edina Szabo, Dora Reglodi, Gabor K Toth

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular neuroscience : MN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Protective Effects of PACAP in a Rat Model of Diabetic Neuropathy.International journal of molecular sciences · 2021
    Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anita K KovacsDepartment of Medical Chemistry, Faculty of Medicine, University of Szeged, Dom Sq 8, Szeged, H-6720, Hungary.ORCID https://orcid.org/0000-0001-9805-1647
Tamas AtlaszDepartment of Anatomy, MTA-PTE PACAP Research Group, Medical School, University of Pecs, Szigeti str 12, Pecs, H-7624, Hungary. attam@gamma.ttk.pte.hu.ORCID https://orcid.org/0000-0002-8112-8633
Dora WerlingDepartment of Anatomy, MTA-PTE PACAP Research Group, Medical School, University of Pecs, Szigeti str 12, Pecs, H-7624, Hungary.ORCID https://orcid.org/0000-0003-0796-7997
Edina SzaboDepartment of Anatomy, MTA-PTE PACAP Research Group, Medical School, University of Pecs, Szigeti str 12, Pecs, H-7624, Hungary.ORCID https://orcid.org/0000-0002-0653-9547
Dora ReglodiDepartment of Anatomy, MTA-PTE PACAP Research Group, Medical School, University of Pecs, Szigeti str 12, Pecs, H-7624, Hungary.ORCID https://orcid.org/0000-0001-5481-5529
Gabor K TothDepartment of Medical Chemistry, Faculty of Medicine, University of Szeged, Dom Sq 8, Szeged, H-6720, Hungary.ORCID https://orcid.org/0000-0002-3604-4385
University of Pecs · HUUniversity of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PACAP is a neuropeptide with widespread distribution and diverse biological functions. It has strong cytoprotective effects mediated mainly through specific PAC1 receptors. Experimental data show protective effects of PACAP in the retina and cornea in several pathological conditions. Although intravitreal injections are a common practice in some ocular diseases, delivery of therapeutic agents in the form of eye drops would be more convenient and would lead to fewer side effects. We have previously shown that PACAP, in the form of eye drops, is able to pass through the ocular barriers and can exert retinoprotective effects. As eye drops represent a promising form of administration of PACAP in ocular diseases, it is important to investigate the stability of PACAP in solutions used in eye drops. In this study, the stability of PACAP1-27 and PACAP1-38 in eye drops was measured in four common media and a commercially available artificial tear solution at both room temperature and +4 °C. Mass spectrometry results show that the highest stability was gained with PACAP1-38 in water and 0.9% saline solution at +4 °C, representing 80-90% drug persistence after 2 weeks. PACAP1-38 in the artificial tear showed very fast degradation at room temperature, but was stable at +4 °C. In summary, PACAP1-38 has higher stability than PACAP1-27, with highest stability at +4 °C in water solution, but both peptides in each medium can be stored for relatively longer periods without significant degradation. These data can provide reference for future therapeutic use of PACAP in eye drops.

Indexed as

Mass SpectrometryOphthalmic SolutionsPituitary Adenylate Cyclase-Activating PolypeptideProtein StabilityTearsTemperatureOphthalmic SolutionsPituitary Adenylate Cyclase-Activating PolypeptideDegradationEye dropsPACAPStability

Identifiers

PMID32323126
PMCPMC8349324
OpenAlexW3017406685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.